Prot #UPCC02614/565193: NU UP16M02: The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A Phase 1/2 Open Label Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma

Project: Research project

Project Details

Effective start/end date5/1/176/30/23


  • University of Pennsylvania (Prot #UPCC02614/565193: NU UP16M02)
  • Novartis Pharmaceuticals Corporation (Prot #UPCC02614/565193: NU UP16M02)